Effectiveness of lipin administration in a comprehensive treatment of community-acquired pneumonia associated with Covid-19

Objective. Тo investigate the effectiveness of Lipin-Biolik therapy on a clinical course of moderate pneumonia associated with COVID-19 as a supplement to the basic therapy at the Department of Pulmonology. Materials and methods. 94 case histories of institutional patients who were treated at the Department of Pulmonology, Chernivtsi Regional Clinical Hospital during 2020-2021 were examined. The patients were divided into two groups: 66 individuals with viral-bacterial pneumonia of a moderate severity associated with COVID-19 (the main group). Their treatment included antibiotics, anticoagulants and intravenous injection of Lipin solution. The control group included 28 patients suffering from pneumonia who received antibiotics and anticoagulants only.Results. Condition of patients after treatment improved in both groups, but in the main group, it was faster than in control one (4-5 faster): shortness of breath decreased, D-dimer in the blood reduced, high blood pressure and the temperature came to normal values, О2 saturation improved. Moreover, by the chest X-ray findings carried out three weeks after treatment, the patients from the main group presented a faster decrease of infiltration areas in the lungs and formation of stable fibrous changes, respectively.Conclusions. The results presented in the article confirm a high effect of Lipin (liposomal forms of natural phosphatidylcholine) for the treatment of viral pneumonias in practical work of a pulmonologist with the aim to reduce the risk of fibrosis formation in the lung tissue, the risk of clot formation and as surfactant-protective therapy.